Loading
Life sciences · Journal article
Frontiers in Oncology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Malakoplakia is an extremely rare chronic inflammatory disorder, most commonly affecting the genitourinary tract. Prostatic malakoplakia is particularly uncommon. Its elevated serum prostate-specific antigen (PSA) levels, magnetic resonance imaging (MRI) findings, and clinical symptoms closely mimic those of prostate cancer, leading to a high risk of misdiagnosis. Here we report a 64-year-old male patient presenting with gross hematuria, frequency, and urgency. Laboratory tests revealed elevated inflammatory markers and a serum PSA of 8.72 ng/mL. Multiparametric MRI (mpMRI) showed a Prostate Imaging Reporting and Data System (PI-RADS) score of 4, raising high suspicion of prostate cancer. Transrectal ultrasound-guided prostate biopsy was performed. Histopathology showed diffuse infiltration by histiocytes containing characteristic Michaelis-Gutmann (MG) bodies with typical morphological features on hematoxylin and eosin (H&E) staining. Immunohistochemistry confirmed prostatic malakoplakia and ruled out malignancy. After treatment with piperacillin sodium, the patient’s symptoms resolved completely. Follow-up at one month showed normalization of inflammatory markers and PSA. This article also narrative literature review 90 cases reported in the past 30 years, summarizing the clinical presentation, imaging features, pathological characteristics, diagnosis, differential diagnosis, and treatment strategies for prostatic malakoplakia. In patients with elevated PSA and mpMRI findings suspicious for prostate cancer, if the lesion shows diffuse symmetric distribution, an intact capsule, and delayed periprostatic enhancement, prostatic malakoplakia should be included in the differential diagnosis. Definitive diagnosis depends on pathological identification of MG bodies. Antibiotic therapy appears to be effective in most reported cases, and the prognosis is generally favorable.